Cardiovascular Journal of Africa

Comprehensive ABC (HbA1c, blood pressure, LDL-C) control and cardiovascular disease risk in patients with type 2 diabetes mellitus and major depressive disorder in a South African managed healthcare organisation

Lovina A Naidoo, Neil Butkow, Paula Barnard-Ashton, Elena Libhaber
Abstract
Aim: Patients with type 2 diabetes mellitus (T2DM) who have suboptimal control of the triad of glucose (A), blood pressure (B) and lipid profile (C) have an increased risk of cardiovascular disease (CVD). Additionally, the presence of major depressive disorder (MDD) can lead to poor outcomes. Therefore, the aim of this study was to assess the role of MDD with ABC control in patients with T2DM in a South African private healthcare setting.
Methods: Healthcare medical claims and electronic health records of 1 211 adult patients with T2DM and/or MDD were analysed for 2019.
Results: Only 24% of the T2DM +/– MDD patients reached a low-density lipoprotein cholesterol (LDL-C) target < 1.8 mmol/l, and only 13% of the T2DM + MDD and 7.1% of T2DM – MDD patients achieved simultaneous ABC targets. The proportion of patients admitted due to macrovascular complications was higher in the T2DM + MDD group (22.8%) compared to the T2DM – MDD (13.1%) and MDD group (9.9%) (p = 0.012). Multivariate logistic regression analysis showed that older patients with T2DM + MDD achieved better glycated haemoglobin and LDL-C control. Significantly more patients with T2DM + MDD (12%) had repeat macrovascular admissions in 2019 compared to the T2DM – MDD patients (2.9%) (p = 0.005).
Conclusion: Despite a managed-care environment, the comprehensive ABC control among patients with T2DM was suboptimal, particularly in those with MDD, placing them at greater risk for CVD events.
Keywords: type 2 diabetes mellitus (T2DM), major depressive disorder (MDD), cardiovascular disease (CVD), ABC control, glycated haemoglobin (HbA1c), systolic blood pressure (SBP), low-density lipoprotein cholesterol (LDL-C), managed healthcare
Submitted: August 25, 2023; Accepted: February 7, 2024; Published Online First: March 25, 2024; Published: December 15, 2024
Cardiovasc J Afr 2024; 35: 402-411
Volume 35, Issue 4
DOI Citation Reference: dx.doi.org/10.5830/CVJA-2024-003
Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Lovina A Naidoo, M Pharm, PhD
Neil Butkow, MSc (Physiology), PhD
School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Paula Barnard-Ashton, MSc OT, PhD
Health Sciences Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Elena Libhaber, MSc, PhD

You need to be logged in to view and download the full text PDF version. Register for a free account?